Fasudil as an adjunctive therapy for patients with stable angina
Claire Braybrook
This article has no abstract so we have provided the first paragraph of the full text.
As many patients with chronic stable angina remain symptomatic despite revascularization and drug therapy, there is a need for new therapeutic strategies. Several small trials of fasudil—a selective Rho-kinase inhibitor—have indicated that this treatment can reduce myocardial ischemia in patients with stable or vasospastic angina. These trials did not, however, include placebo controls, and they failed to report the use of concomitant cardiovascular drugs.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
L-DOPA, dyskinesia and striatal plasticityNature Neuroscience News and Views (01 May 2003)
